Imaging services firm RadNet will participate in a clinical trial for E2609, an investigational drug being developed by Japanese pharmaceutical firm Eisai for the treatment of Alzheimer's disease.
Multiple RadNet centers in Los Angeles and Baltimore will provide MRI and beta-amyloid PET/CT capabilities for the phase I trial, which will evaluate the biomarker effects of the beta-site amyloid precursor protein-cleaving enzyme (BACE) inhibitor.
Specifically, the trial will explore whether E2609 changes the levels of beta amyloid in patients identified as having subjective memory complaints and mild cognitive impairment or mild dementia due to Alzheimer's disease, RadNet said.
The trial will use GE Healthcare's F-18 flutemetamol investigational PET agent to help select patients.
